The primary objective was to demonstrate noninferiority of telaprevir twice daily versus every 8 hours in producing a sustained virological response 12 weeks after the end of therapy ( SVR12 ) ( based on a -11 % lower limit of the 95 % lower confidence interval for the difference between groups ) .